Product image of Melleva (Ethinylestradiol, Levonorgestrel | Lactose) supplied by GNH India

Melleva

Active Ingredient:
Ethinylestradiol, Levonorgestrel | Lactose
Origin:
EU

Melleva (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol, the active ingredient in Melleva, is a combined oral contraceptive presented as an oral tablet for oral use. It is formulated together with levonorgestrel to provide hormonal contraception for women of reproductive age, preventing unintended pregnancy through multiple mechanisms of action.

GNH India supplies Melleva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across regions.

Manufacturer / TM Owner

Exeltis Germany Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Melleva, a combined oral contraceptive, is used to prevent pregnancy by modulating the hormonal axis.

  • Contraception: prevents unintended pregnancy in women of reproductive age.
  • Cycle regulation: helps achieve more regular menstrual bleeding patterns.
  • Acne improvement: may reduce acne associated with hormonal fluctuations.

How It Works

  • Melleva combines ethinylestradiol, a synthetic estrogen, with levonorgestrel, a progestogen. The estrogen component suppresses the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), while the progestogen thickens cervical mucus and alters the endometrial lining, together preventing ovulation and implantation.

Side Effects

Melleva may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: discomfort or swelling of the breasts.
  • Headache: occasional throbbing or tension‑type pain.
  • Breakthrough bleeding: spotting between periods.
  • Weight change: slight increase or decrease in body weight.
  • Mood changes: irritability or mood swings.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins.
  • Arterial thrombosis: clot formation in arteries, potentially causing stroke.
  • Hypertension: elevated blood pressure.
  • Liver tumor: benign hepatic adenoma.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.

Precautions & Warnings

Before prescribing Melleva, clinicians should consider several safety factors.

  • Assess cardiovascular risk: evaluate history of thrombosis before prescribing.
  • Avoid smoking: especially in women over 35 years of age.
  • Monitor blood pressure: check regularly during use.
  • Consider liver function: adjust if hepatic disease is present.
  • Review medication list: identify potential interactions.
  • Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Avoid Interactions

Melleva can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness.
  • Rifampin: decreases hormone levels, increasing risk of unintended pregnancy.
  • Certain HIV protease inhibitors: may increase the risk of thrombosis.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles (e.g., ketoconazole): may increase hormone concentrations.
  • St. John’s wort: may lower contraceptive effectiveness.
  • Antibiotics such as tetracycline: may slightly reduce absorption of the hormones.

Frequently Asked Questions

Melleva is a combined oral contraceptive indicated for the prevention of unintended pregnancy in women of reproductive age. It works by inhibiting ovulation and creating conditions in the cervix and uterus that reduce the likelihood of fertilisation and implantation.

Ethinylestradiol, a synthetic estrogen, suppresses the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), preventing ovulation. Levonorgestrel, a progestogen, thickens cervical mucus and alters the endometrial lining, making it less suitable for implantation. Together they provide reliable hormonal contraception.

The dosing regimen for Melleva is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily for a defined cycle, but the exact schedule and any missed‑dose instructions should be provided by the prescriber.

Melleva is classified as pregnancy category X, meaning it must not be used during pregnancy because it can cause harm to the fetus. Women who are breastfeeding should consult their healthcare provider, as hormonal contraceptives may affect milk production and infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Melleva contains the standard dose combination of ethinylestradiol and levonorgestrel, which is widely used and well‑studied. Compared with newer formulations that may use different progestogens or lower estrogen doses, Melleva offers a familiar efficacy and side‑effect profile, making it a reliable choice for many women.

Melleva tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct heat, and ensure the container is tightly closed to maintain product stability.

Melleva is taken orally, usually once each day at the same time, with or without food. The tablets are swallowed whole with a glass of water. Patients should follow the specific cycle schedule provided by their prescriber.

The most serious risks include venous or arterial thromboembolism, hypertension, and rare liver tumors. Women with a history of clotting disorders, smoking, or certain cardiovascular conditions should be evaluated carefully before starting Melleva.

Melleva is contraindicated in women who are pregnant, have known or suspected estrogen‑dependent tumors, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or who are smokers over the age of 35. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel | Lactose

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT